Gain Therapeutics, Inc.
$2.12
▼
-4.64%
2026-04-21 07:00:02
gaintherapeutics.com
NGM: GANX
Explore Gain Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$89.98 M
Current Price
$2.12
52W High / Low
$4.34 / $1.41
Stock P/E
—
Book Value
$0.44
Dividend Yield
—
ROCE
-96.12%
ROE
-1.56%
Face Value
—
EPS
$-0.61
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
20
Beta
0.11
Debt / Equity
3.94
Current Ratio
6.63
Quick Ratio
6.63
Forward P/E
-2.89
Price / Sales
—
Enterprise Value
$55.93 M
EV / EBITDA
-2.99
EV / Revenue
—
Rating
Strong Buy
Target Price
$7.6
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | OS Therapies Incorporated | $1.38 | — | $58.43 M | — | 582.87% | 614.26% | $2.57 / $1.15 | $-0.16 |
| 2. | Genprex, Inc. | $1.16 | — | $10.45 M | — | -194.32% | -3.39% | $55 / $1.15 | $3.78 |
| 3. | Recursion Pharmaceuticals, Inc. | $3.69 | — | $1.95 B | — | -48.86% | -59.54% | $7.18 / $2.8 | $2.14 |
| 4. | Rocket Pharmaceuticals, Inc. | $3.86 | — | $421.21 M | — | -76.11% | -60.27% | $8.26 / $2.19 | $2.56 |
| 5. | Fennec Pharmaceuticals Inc. | $6.73 | — | $232.02 M | — | -10.57% | -65.82% | $9.92 / $5.02 | $1.04 |
| 6. | Fulcrum Therapeutics, Inc. | $7.94 | — | $552.12 M | — | -24% | -25.3% | $15.74 / $2.92 | $5.24 |
| 7. | Matinas BioPharma Holdings, Inc. | $0.55 | — | $3.52 M | — | -202.13% | -1.67% | $3.09 / $0.48 | $1.09 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -4.47 M | -4.79 M | -5.09 M | -4.37 M | -3.33 M | — |
| Net Profit | -4.54 M | -5.28 M | -5.81 M | -4.53 M | -3.77 M | — |
| EPS in Rs | -0.11 | -0.12 | -0.14 | -0.11 | -0.09 | -0.17 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0.06 M | 0.14 M |
| Operating Profit | -18.71 M | -20.35 M | -22.25 M | -17.78 M |
| Net Profit | -20.16 M | -20.41 M | -22.27 M | -17.59 M |
| EPS in Rs | -0.47 | -0.48 | -0.52 | -0.41 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 22.82 M | 12.12 M | 18.61 M | 24.1 M |
| Total Liabilities | 4.25 M | 4.78 M | 6.03 M | 5.22 M |
| Equity | 18.56 M | 7.34 M | 12.58 M | 18.88 M |
| Current Assets | 22.24 M | 11.6 M | 17.78 M | 21.09 M |
| Current Liabilities | 3.35 M | 3.91 M | 4.95 M | 4.13 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -18.47 M | -18.87 M | -18.87 M | -14.69 M |
| Investing CF | 0 M | 4.98 M | 10.22 M | -14.77 M |
| Financing CF | 28.45 M | 13.01 M | 12.64 M | -0.08 M |
| Free CF | -18.47 M | -18.9 M | -18.88 M | -14.81 M |
| Capex | — | -0.02 M | -0.02 M | -0.12 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | -60.62% | — | — |
| Earnings Growth % | 8.34% | -26.59% | — | — |
| Profit Margin % | — | -40354.33% | -12555.13% | — |
| Operating Margin % | — | -40328.26% | -12688.1% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | -40176.79% | -12642.3% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.